Nanochelating technology introduces anti-cancer agent
محل انتشار: نهمین کنگره بین المللی سرطان پستان
سال انتشار: 1392
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 340
نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
این مقاله در بخشهای موضوعی زیر دسته بندی شده است:
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
ICBCMED09_246
تاریخ نمایه سازی: 29 فروردین 1397
چکیده مقاله:
In spite of all the efforts and researches on anticancer therapeutics, an absolute treatment is still a myth. It is evident that current drugs are not able to efficiently target the underlying pathogenesis on higher levels of cellular signalling and by affecting different pathways. So this multifactorial natured medusa has the upper hand. For the first time, we synthesized BCc1 nano complex based on the novel nanochelating technology and evaluated its anticancer effects, in vivo and in vitro. The results revealed an intelligent, targeted and multi-functional antineoplastic behavior of this nano complex considering that it showed low normal cell cytotoxicity and high malignant growth suppression in cellular and animal models by a different performance from other medications. Thus, BCc1 can be considered as a profitable candidate for further complementary evaluations to introduce a new generation of anticancer medications with completely superior function
نویسندگان
Maryam Hafizi
Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.- Cancer Research Center , Shahid Beheshti University of Medical Sciences, Tehran, Iran
Somayeh Kalanaky
Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
Saideh Fakharzadeh
Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran.
Mohammad Vasei
Department of Pathology Tehran University of Medical Sciences,Tehran, Iran